About PHYTRIXX

"I started in a wet lab, not in front of a screen. My early work was in biopharmaceutical R&D — producing monoclonal and polyclonal antibodies, running recombinant protein expression and purification, validating every batch by ELISA and SDS-PAGE. That background matters more than it might seem for a computational science company, because it means I've seen the gap firsthand between what a docking score predicts and what actually survives contact with a real biological system.

Alongside that bench work, I trained extensively in NGS pipelines, structural bioinformatics, and computational drug design — molecular docking, molecular dynamics, network pharmacology, and ADMET prediction. I built PHYTRIXX to sit exactly at that intersection: traditional herbal knowledge on one side, rigorous computational validation on the other, and someone who's actually worked in both worlds connecting them.

Before founding PHYTRIXX, I ran independent computational research projects that became the proof of concept for this company — an AI-driven virtual screening study identifying candidate compounds for Duchenne Muscular Dystrophy, and a structural analysis of VEGF–VEGFR1 binding mechanisms. Every Ashwagandha or turmeric validation report PHYTRIXX produces today follows that same rigor.